Historically, if MLH1 is absent on IHC for CRC tumors, subsequent testing can take several directions: (1) germline MLH1 testing; (2) tumor MLH1 methylation testing; (3) tumor testing for the BRAF p.V600E PV based on its association with MLH1 methylation status (3, 12). This evidence concerns the gene BRAF and neoplasm.